BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Relapsing-Remitting Multiple SclerosisMultiple Sclerosis
Interventions
DRUG

dimethyl fumarate

Days 1-7: 120 mg three times a day (TID) for a total daily dose of 360 mg. Day 8 to Week 24: 240 mg TID for a total daily dose of 720 mg. Drug supplied as a capsule taken orally.

Trial Locations (16)

Unknown

Research Site, Gilbert

Research Site, Phoenix

Research Site, Danbury

Research Site, Atlanta

Research Site, Fort Wayne

Research Site, Baltimore

Research Site, Boston

Research Site, Golden Valley

Research Site, Teaneck

Research Site, Patchogue

Research Site, Cleveland

Research Site, Dayton

Research Site, Portland

Research Site, Cordova

Research Site, Franklin

Research Site, Milwaukee

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY